High levels of TYRO3 expression correlated with poor response to therapy in patients with HER2-positive breast cancer and exogenous expression of TYRO3 was sufficient to confer resistance to the small molecule HER2 inhibitor lapatinib in 2 of 3 breast cancer cell lines [40]. Here, TYRO3 is linked to breast carcinoma.